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other treatment related effects such as nausea. The present study
was designed to estimate the utility decrement associated with
increasing severities of anaemia. METHODS: Existing trial data
was summarized in order to deﬁne health states related to the
following haemoglobin levels: 7.0–8.0; 8.0–9.0; 9.0–10.0;
10.0–10.5; 10.5–11.0; 11.0–12.0; and 12+g/dL. These health
states were based on the FACT-An fatigue related items and were
reviewed by clinicians and two quality of life experts. Forty inter-
views with the general public (recruited through advertisements)
were conducted where participants were asked to rate the health
states using a visual analogue scale (VAS) and standard gamble
(SG). RESULTS: Mean (+95% CI) utility values were calculated
for each health state anchored against death. The VAS scores
ranged from 19.3 ± 3.9 for 7–8g/dL Hb to 53.8 3 ± 6.7 for 12+
g/dL Hb. The standard gamble derived utility values showed a
broadly linear change from 0.59 ± 0.10 for 7–8g/dL Hb to 0.75
± 0.09 for 12+g/dL Hb. CONCLUSIONS: The health state
utility scores show a linear decrement in line with worsening
anaemia. These data underline the importance of cancer related
fatigue for the general public.
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OBJECTIVES: Anaemia is a common complication in cancer
patients undergoing chemotherapy. Although quality-of-life
(QoL) in CRA has been studied, utility values related to anaemia
severity are lacking. The UK National Institute for Clinical
Excellence (NICE) requests cost-utility analysis based on quality-
adjusted life-years (QALY’s) incorporating utilities elicited using
public preferences. The objective was to use an appropriate
method to estimate the impact of CRA, from a societal perspec-
tive. METHODS: A time-trade-off (TTO) questionnaire was
designed and administered to a sample of laypeople: CRA health
states were deﬁned and described, based on the EuroQoL (EQ-
5D) instrument, and the Functional Assessment of Cancer
Therapy—Anaemia (FACT-An) instrument, and validated by
clinical experts and cancer patients who had experienced
anaemia. These descriptions were valued using the TTO elicita-
tion method. Written informed consent was obtained and trained
interviewers conducted surveys during February–March, 2004.
RESULTS: In total, 110 respondents were interviewed; ﬁnal
analyses were performed on 106 respondents’ data. Resultant
utility scores were converted to ratios, reﬂecting the baseline of
“cancer and chemotherapy, with no anaemia”. Mean utility
scores [SE] are 0.856 [0.014] for the no-anaemia state, and 0.781
[0.016], 0.615 [0.020] and 0.481 [0.020] for mild, moderate and
severe anaemia states, respectively (Ratios of 1.00, 0.91, 0.72,
and 0.56, respectively). CONCLUSIONS: This study strongly
highlights a societal view that severity of cancer-related anaemia
will signiﬁcantly affect patient utility. For example, a change
from no-anaemia to severe anaemia is predicted to approxi-
mately halve utility, independent of other factors. TTO 
appears to be a valid, and sufﬁciently sensitive method to high-
light this effect. The ratios of relative effect are applicable to a
range of “baseline” cancer utilities as multiplicative factors 
to estimate impact of anaemia within this broader context. 
These results could be incorporated within appraisals of thera-
pies for CRA, and satisfy certain health technology assessment
criteria.
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OBJECTIVES: Blood transfusion and rh-EPO are alternative
treatment options for CRA. Potential beneﬁts of rh-EPO treat-
ment include improved health outcomes, but also more conve-
nient administration. The objective was to elicit public
preference scores associated with differences in these aspects of
treatment, and subsequently use these “valued preferences”
within a willingness-to-pay (WTP) analysis of cost-effectiveness
of NeoRecormon (rh-EPO beta) versus transfusion. METHODS:
A discrete choice experiment (DCE) was designed and adminis-
tered to a sample of laypeople. Important aspects of treatment
were deﬁned through a literature review, plus input from expert
clinician and patient interviews. An out-of-pocket cost attribute
was included in order to estimate WTP values. Lay people were
surveyed during February–March, 2004. A random effects probit
model was used to analyse the data. WTP values for aspects of
treatment were obtained by estimating the marginal rate of sub-
stitution between treatment attributes and the cost coefﬁcient.
Mean values of a unit improvement in each attribute level were
used in an economic welfare analysis of the value of shifting from
transfusion to NeoRecormon. RESULTS: A total of 110 respon-
dents completed the DCE questionnaire. Final analyses were per-
formed on 1086 observations, and showed high consistency,
reliability, and face-validity. The following preferences were sig-
niﬁcant predictors of choice (p < 0.001): Effectiveness: Higher
level of relief from fatigue; Administration of treatment: Lower
duration, subcutaneous/intravenous versus cannula injection,
and GP versus hospital location; Safety: Lower risk of infec-
tion/allergic reaction; and Lower cost. Attribute levels were
valued higher for NeoRecormon than for transfusion. This is
reﬂected in an incremental welfare value of GBP368[95% CI:
GBP318-GBP419]. CONCLUSIONS: This study shows that the
public value the favourable attributes of treatment with rh-EPO,
and indicates a likely patient preference for treatment with Neo-
Recormon over blood transfusion. This type of WTP analysis
could be used to aid decisions regarding optimal management of
CRA.
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OBJECTIVES: Anastrozole provides a treatment alternative for
patients with EBC who cannot tolerate tamoxifen or in whom
the drug is contraindicated. This study aimed to examine the
value patients place on the ability of a treatment to decrease the
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risk of breast cancer recurrence and mortality, while considering
the side effect proﬁle of the treatment. METHODS: A total of
85 women aged 50–83 (mean 61) years were recruited from the
Australian general public. Participants completed questions
regarding breast cancer experience and undertook a discrete
choice task. The attributes used in the WTP scenarios included
values for risk of breast cancer recurrence, mortality, hot ﬂushes,
vaginal abnormalities, deep vein thrombosis (DVT) and fracture,
and also cost. The risk estimates against placebo were derived
using indirect comparisons. RESULTS: A total of 74 subjects
provided evaluable data. Eleven subjects were excluded because
they were non-traders (3) or irrational in their choice task. The
total WTP for anastrozole over placebo was AUS$906.00 per
month (95% CI: 380.7–1548.7) for 4–5 years. This included a
WTP of AUS$794.20, AUS$481.70, AUS$38.20 and AUS$32.10
for the reduced risk of breast cancer recurrence, mortality, 
hot ﬂushes and vaginal abnormalities, respectively. For DVT 
and fracture, which favoured placebo, negative WTPs of 
-AUS$316.00 and -AUS$124.20, respectively, were obtained.
CONCLUSIONS: Subjects were willing to pay an average of
AUS$906.00 per month for 4–5 years for access to a treatment
with the attributes of anastrozole. The reduced risk of breast
cancer recurrence and mortality were the main drivers for the
treatment; however, increased risk of fracture and DVT were also
of concern to participants.
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OBJECTIVES: To document and compare actual treatment prac-
tices, outcomes (hematopoietic response rates, Hb changes,
transfusions, hospital care), and health care costs of Epoetin alfa
and Darbepoetin alfa in the treatment of chemotherapy-related
anemia in cancer patients in Sweden. METHODS: A retrospec-
tive chart review was performed at 3 Swedish hospitals. A total
of 59 patients with cancer who developed chemotherapy-related
anemia and received erythropoiesis-stimulating agent treatment
were identiﬁed: 29 patients initially received epoetin alfa and 30
patients initially received darbepoetin alfa. Data were collected
on dosage and duration of treatment with these agents, hemo-
globin (Hb) response measures, red blood cell transfusions, and
health care resource consumption and analyzed at follow-up
time points of 28, 56, 84, and 112 days. RESULTS: A signiﬁ-
cantly faster Hb response and increase in Hb levels was observed
in patients treated with eEpoetin alfa compared to patients
treated with Darbepoetin alfa. Lower dosages are used in actual
clinical practice than recommended in Swedish treatment guide-
lines. No signiﬁcant differences in resource utilization or in
health care costs between epoetin alfa- or darbepoetin alfa-
treated patients were found. At a follow-up of 112 days, the
mean treatment cost per patient was SEK74,701 (approximately
US$9800 or 8300€) with epoetin alfa and SEK85,285 (approx-
imately US$11,000 or 9500€) with darbepoetin alfa. Drug acqui-
sition and administration costs accounted for 81% and 67% of
total costs for epoetin alfa- and darbepoetin alfa-treated patients,
respectively, with remaining costs accounted for by hospitaliza-
tion and transfusions. CONCLUSIONS: Epoetin alfa was asso-
ciated with a signiﬁcantly faster Hb response, and signiﬁcantly
higher increases in Hb levels compared with darbepoetin alfa, as
used clinically. While the costs are in favor of epoetin alfa, they
are not signiﬁcantly different for the two treatment arms. Lower
dosages of both agents are used in actual clinical practice than
recommended in Swedish treatment guidelines.
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OBJECTIVES: To systematically evaluate the impact of screen-
ing adherence on clinical effectiveness and cost-effectiveness of
cervical cancer screening (CCS) in Germany using a decision ana-
lytic approach. METHODS: A decision-analytic Markov model
was used to evaluate long-term clinical and economic outcomes
for the following CCS strategies: 1) no screening; 2) conventional
Papanicolaou test with manual smear analysis (PAP); 3) PAP
with automated smear analysis (AA); 4) liquid-based preparation
(LP) with manual smear analysis; and 5) LP in combination with
AA. German clinical, epidemiological and economic data were
used. German clinical practice in screening, diagnosis, and treat-
ment of cervical cancer and its precursors were considered. Cal-
culated outcomes were detected/prevented cervical cancer cases
and deaths, life expectancy, lifetime costs, and discounted incre-
mental cost-effectiveness ratios (ICER). We adopted a societal
perspective with a three percent (3%) annual discount rate. In
the absence of individual data, screening adherence was modeled
to be independent from screening history. RESULTS: In women
adherent to screening, annual PAP saved 94 life days, when com-
pared to “no screening”, and new CCS strategies saved addi-
tional 0.5 days. Assuming 50% adherence annual screening with
new strategies would save additional 3 days compared to annual
PAP screening with 50% adherence and would be nearly equally
effective as annual PAP with complete adherence. Assuming a
societal willingness-to-pay of 50,000€/LYS, annual PAP com-
pared to “no screening” was cost-effective independent of
screening adherence. Annual screening with new strategies com-
pared to PAP was not cost-effective in adherent women, but may
be cost-effective with 65% (AA) or 40% (LP or LP + AA) or
lower adherence. CONCLUSIONS: For the current clinical stan-
dard of annual cervical cancer screening in Germany, PAP screen-
ing is both medical effective and cost-effective independent of
adherence. New CCS strategies may be effective and cost-
effective in women who do not regularly attend annual screen-
ing programs.
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OBJECTIVES: Develop and categorise pharmaceutical care
activities that contribute to the care of patients receiving cancer
chemotherapy. METHODS: A retrospective survey of clinical
